AtriCure/$ATRC
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About AtriCure
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. Geographically, it generates a majority of its revenue from the United States. Cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures.
Ticker
$ATRC
Sector
Primary listing
Industry
Health Care Equipment & Supplies
Headquarters
Employees
1,300
ISIN
US04963C2098
Website
AtriCure Metrics
BasicAdvanced
$1.6B
-
-$0.81
1.65
-
Price and volume
Market cap
$1.6B
Beta
1.65
52-week high
$43.11
52-week low
$20.20
Average daily volume
509K
Financial strength
Current ratio
4.108
Quick ratio
2.666
Long term debt to equity
16.403
Total debt to equity
17.028
Interest coverage (TTM)
-5.70%
Profitability
EBITDA (TTM)
-15.685
Gross margin (TTM)
74.76%
Net profit margin (TTM)
-7.95%
Operating margin (TTM)
-7.30%
Effective tax rate (TTM)
-2.91%
Revenue per employee (TTM)
$370,000
Management effectiveness
Return on assets (TTM)
-3.70%
Return on equity (TTM)
-8.38%
Valuation
Price to revenue (TTM)
3.103
Price to book
3.44
Price to tangible book (TTM)
9.05
Price to free cash flow (TTM)
-2,217.156
Free cash flow yield (TTM)
-0.05%
Free cash flow per share (TTM)
-1.43%
Growth
Revenue change (TTM)
15.79%
Earnings per share change (TTM)
1.08%
3-year revenue growth (CAGR)
18.35%
10-year revenue growth (CAGR)
15.68%
3-year earnings per share growth (CAGR)
-10.39%
10-year earnings per share growth (CAGR)
4.72%
What the Analysts think about AtriCure
Analyst ratings (Buy, Hold, Sell) for AtriCure stock.
Bulls say / Bears say
AtriCure reported a 13.6% year-over-year revenue increase in Q1 2025, reaching $123.62 million, surpassing analyst expectations. (Zacks Equity Research)
The company's pain management franchise grew 32% worldwide in 2024, driven by new product launches like cryoSPHERE+ and cryoSPHERE MAX probe. (TipRanks)
Institutional investors, including Natixis and Raymond James Financial Inc., have recently increased their stakes in AtriCure, indicating confidence in the company's growth prospects. (MarketBeat, MarketBeat)
AtriCure's U.S. Minimally Invasive Ablation segment faces competitive pressure due to increased adoption of pulsed field ablation techniques, potentially impacting future growth. (GuruFocus)
The company reported a net loss of $15.57 million in Q4 2024, with a net profit margin of -12.53%, indicating ongoing profitability challenges. (Google Finance)
BTIG adjusted its price target for AtriCure from $58 to $53, reflecting concerns over sector performance and competitive pressures. (Investing.com)
Data summarised monthly by Lightyear AI. Last updated on 4 Jun 2025.
AtriCure Financial Performance
Revenues and expenses
AtriCure Earnings Performance
Company profitability
AtriCure News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for AtriCure stock?
AtriCure (ATRC) has a market cap of $1.6B as of June 20, 2025.
What is the P/E ratio for AtriCure stock?
The price to earnings (P/E) ratio for AtriCure (ATRC) stock is 0 as of June 20, 2025.
Does AtriCure stock pay dividends?
No, AtriCure (ATRC) stock does not pay dividends to its shareholders as of June 20, 2025.
When is the next AtriCure dividend payment date?
AtriCure (ATRC) stock does not pay dividends to its shareholders.
What is the beta indicator for AtriCure?
AtriCure (ATRC) has a beta rating of 1.65. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.